PROFUSA INC (PFSA) Stock Price, Forecast & Analysis
NASDAQ:PFSA • US74319X1081
PFSA Key Statistics, Chart & Performance
The current stock price of PFSA is 1.22 USD. In the past month the price decreased by -83.07%.
PFSA Technical Analysis
PFSA Financial Highlights
Over the last trailing twelve months PFSA reported a non-GAAP Earnings per Share(EPS) of -278.72. The EPS decreased by -2240.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -919.85% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PFSA Forecast & Estimates
PFSA Ownership
PFSA Latest News, Press Relases and Analysis
PFSA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 20.25 | 202.161B | ||
| ISRG | INTUITIVE SURGICAL INC | 49.59 | 180.008B | ||
| SYK | STRYKER CORP | 25.53 | 147.637B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.63 | 112.339B | ||
| IDXX | IDEXX LABORATORIES INC | 44.59 | 52.758B | ||
| BDX | BECTON DICKINSON AND CO | 11.21 | 50.332B | ||
| EW | EDWARDS LIFESCIENCES CORP | 28.89 | 49.848B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.71 | 38.246B | ||
| RMD | RESMED INC | 20.93 | 37.448B | ||
| DXCM | DEXCOM INC | 29.46 | 29.01B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PFSA
Company Profile
Profusa Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in New York City, New York and currently employs 0 full-time employees. The company went IPO on 2021-12-20. Profusa, Inc. is a commercial stage digital health company. The firm is engaged in the development of a new generation of biointegrated sensors that potentially empower the individual with the ability to monitor their body chemistry. The Company’s technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. Its first clinical offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels in various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery.
Company Info
PROFUSA INC
207 West 25Th St, 9Th Floor
New York City NEW YORK US
Employees: 0
Phone: 12124949022
PROFUSA INC / PFSA FAQ
Can you describe the business of PROFUSA INC?
Profusa Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in New York City, New York and currently employs 0 full-time employees. The company went IPO on 2021-12-20. Profusa, Inc. is a commercial stage digital health company. The firm is engaged in the development of a new generation of biointegrated sensors that potentially empower the individual with the ability to monitor their body chemistry. The Company’s technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. Its first clinical offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels in various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery.
What is the current price of PFSA stock?
The current stock price of PFSA is 1.22 USD. The price decreased by -3.17% in the last trading session.
What is the dividend status of PROFUSA INC?
PFSA does not pay a dividend.
How is the ChartMill rating for PROFUSA INC?
PFSA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
On which exchange is PFSA stock listed?
PFSA stock is listed on the Nasdaq exchange.
What is the market capitalization of PFSA stock?
PROFUSA INC (PFSA) has a market capitalization of 1.50M USD. This makes PFSA a Nano Cap stock.
When does PROFUSA INC (PFSA) report earnings?
PROFUSA INC (PFSA) will report earnings on 2026-03-23.